NCT06797999 (ADCElerate1) is a Phase 1, PHASE2 clinical trial of Antibody-drug conjugate (ADC) in Metastatic Soft Tissue Sarcoma, sponsored by Adcendo ApS.

Who is sponsoring NCT06797999?

NCT06797999 is sponsored by Adcendo ApS.

What drugs are being tested in NCT06797999?

Interventions in NCT06797999: Antibody-drug conjugate (ADC).

What condition does NCT06797999 study?

NCT06797999 studies Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma.

Is NCT06797999 still recruiting?

NCT06797999 is currently recruiting now. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT06797999: ADCElerate1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Recruiting now Phase 1, PHASE2 Last updated 28 January 2026

What this trial tests

Phase 1, PHASE2 trial testing Antibody-drug conjugate (ADC) in Metastatic Soft Tissue Sarcoma in 270 participants. Currently enrolling.

Timeline

5 June 2025

Primary endpoint
27 February 2029

27 February 2029

Quick facts

Lead sponsor	Adcendo ApS
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	270
Start date	5 June 2025
Primary completion	27 February 2029
Estimated completion	27 February 2029
Sites	8 locations across France, Belgium, United Kingdom, Germany, United States

Drugs / interventions tested

Antibody-drug conjugate (ADC) — full drug profile →

Conditions studied

Metastatic Soft Tissue Sarcoma — all drugs for Metastatic Soft Tissue Sarcoma →
Unresectable Soft Tissue Sarcoma — all drugs for Unresectable Soft Tissue Sarcoma →

Sponsor

Adcendo ApS — full company profile →

Who can join

18 and older, any sex, with Metastatic Soft Tissue Sarcoma or Unresectable Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: antibody-drug conjugates in cancer therapy.
Doffe F, Deng X, Shen Z, Xue E, et al · · 2026 · PMID 42070121 · DOI 10.1080/2162402x.2026.2667160
Molecular epidemiology of the expression of urokinase plasminogen activator receptor-associated protein (uPARAP) in mesenchymal malignancies.
Wang CC, Barkholt P, Wozniak A, Vanleeuw U, et al · · 2026 · PMID 41734474 · DOI 10.1016/j.tranon.2026.102708
Targeting uPARAP with an Antibody-Drug Conjugate Exhibits Efficacy against Mesothelioma and Synergizes with Cisplatin.
Çakılkaya P, Egeland Larsen IM, Jiang Q, Sandal Nørregaard K, et al · · 2026 · PMID 41366685 · DOI 10.1158/2767-9764.crc-25-0381
Mannose Receptor C type 2 influences autoimmune neuroinflammation and blood-brain barrier integrity
Zierfuss B, Käch M, Sugère C, Morvan M, et al · · 2025 · DOI 10.21203/rs.3.rs-6917781/v1

Verify or expand the search:

Other recruiting trials for Metastatic Soft Tissue Sarcoma

Currently open trials in the same condition.

NCT06498648 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis · Phase 1, PHASE2 · recruiting
NCT05836571 — Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft T · Phase 2 · active not recruiting
NCT05075993 — Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metast · Phase 1 · active not recruiting
NCT03965234 — Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases · Phase 1, PHASE2 · recruiting
NCT04028063 — Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas · Phase 2 · recruiting

Other Adcendo ApS trials

Trials by the same sponsor.

NCT07362888 — First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06597721 — ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06797999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adcendo ApS
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06797999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing